Chemistry:ZD6126
From HandWiki
Short description: Chemical compound
 | |
 | |
| Clinical data | |
|---|---|
| Other names | ANG 453; AZD 6126; N-Acetylcolchicinol dihydrogenphosphate |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C20H24NO8P |
| Molar mass | 437.385 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
ZD6126 is a vascular-targeting agent and a prodrug of N-acetylcolchinol, related to colchicine.[1] It has shown promising results on tumors in mice.[2]
A phase I clinical trial identified gastrointestinal and cardiac effects as limiting dosing.[3] Two phase II clinical trials were suspended investigating ZD6126 in metastatic renal cell carcinoma and metastatic colorectal cancer.[4]
ZD6126 was being investigated by AstraZeneca as a vascular disrupting agent (VDA). However, the trials were halted, after it became apparent that ZD6126 was too cardiotoxic at the required doses.[5]
References
- ↑ "ZD6126". NCI Drug Dictionary. U.S. National Cancer Institute. http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=353153.
- ↑ "Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice". Cancer Research 62 (13): 3711–5. July 2002. PMID 12097279. http://cancerres.aacrjournals.org/cgi/content/abstract/62/13/3711.
- ↑ "Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors". Investigational New Drugs 26 (2): 159–67. April 2008. doi:10.1007/s10637-008-9112-9. PMID 18219445.
- ↑ "ZD6126". ClinicalTrialsGov. U.S. National Library of Medicine. http://www.clinicaltrials.gov/ct2/results?term=zd6126.
- ↑ "Vascular disrupting agents". Bioorganic & Medicinal Chemistry 15 (2): 605–15. January 2007. doi:10.1016/j.bmc.2006.10.020. PMID 17070061.
 |  |
